It is very uncertain whether HALOPERIDOL changes adverse effects compared with COMBINATIONS: c. HALOPERIDOL + MIDAZOLAM (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects compared with COMBINATIONS: f. OLANZAPINE + MAGNESIUM VALPROATE (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects compared with COMBINATIONS: h. RISPERIDONE + CLONAZEPAM (very low certainty).
HALOPERIDOL showed no clear difference in adverse effects: specific compared with COMBINATIONS: e. HALOPERIDOL + RISPERIDONE (low certainty).
The review found no eligible studies for this question.
HALOPERIDOL showed no clear difference in adverse effects: specific ‐ seizure compared with COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE (low certainty).
HALOPERIDOL may leads to higher adverse effects: specific ‐ acute dystonia compared with COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE (low certainty).
It is very uncertain whether RISPERIDONE changes adverse effects: movement disorders, over 24 hours compared with COMBINATION: a. RISPERIDONE + OXCARBAZEPINE (very low certainty).
It is very uncertain whether RISPERIDONE changes adverse effects: movement disorders, over 24 hours compared with COMBINATION: b. RISPERIDONE + VALPROIC ACID (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia (only reported if occurred in… compared with COMBINATIONS: b. HALOPERIDOL + LORAZEPAM (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ hypertonia/rigidity (only reported if… compared with COMBINATIONS: b. HALOPERIDOL + LORAZEPAM (very low certainty).